prazosin has been researched along with Parkinson Disease in 8 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
Excerpt | Relevance | Reference |
---|---|---|
"Mild dizziness/lightheadedness was more common in the TZ group, and three participants taking TZ dropped out because of dizziness and/or orthostatic hypotension." | 3.11 | A pilot to assess target engagement of terazosin in Parkinson's disease. ( Brinker, AN; Ernst, SE; Liu, L; Magnotta, VA; Narayanan, NS; Rauckhorst, AJ; Schultz, JL; Simmering, JE; Taylor, EB; Tayyari, F; Uc, EY; Welsh, MJ; Xu, J, 2022) |
" Additional dose-response analyses were carried out." | 1.62 | Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease. ( Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ, 2021) |
"We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs." | 1.51 | Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases. ( Cai, R; Chen, Z; Consiglio, A; Fernandez-Carasa, I; Gao, L; Han, Y; Ji, X; Li, Y; Liu, L; Narayanan, NS; Polgreen, PM; Raya, A; Schultz, JL; Simmering, JE; Su, W; Welsh, MJ; Yuan, Y; Zhang, Y; Zhao, C, 2019) |
"Further, when the HAL (1 mg/kg) catalepsy score was maximal (at 120 min), the rats were subjected to cold stress (3 degrees C for 10 min) or treated with NA, AD (2 micrograms/kg, i." | 1.29 | Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines. ( Chopde, CT; Hote, MS; Mandhane, SN; Muthal, AV, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 3 (37.50) | 2.80 |
Authors | Studies |
---|---|
Schultz, JL | 2 |
Brinker, AN | 1 |
Xu, J | 1 |
Ernst, SE | 1 |
Tayyari, F | 1 |
Rauckhorst, AJ | 1 |
Liu, L | 3 |
Uc, EY | 1 |
Taylor, EB | 1 |
Simmering, JE | 3 |
Magnotta, VA | 1 |
Welsh, MJ | 3 |
Narayanan, NS | 3 |
Sardoiwala, MN | 1 |
Mohanbhai, SJ | 1 |
Karmakar, S | 1 |
Choudhury, SR | 1 |
Cai, R | 1 |
Zhang, Y | 1 |
Li, Y | 1 |
Fernandez-Carasa, I | 1 |
Consiglio, A | 1 |
Raya, A | 1 |
Polgreen, PM | 1 |
Yuan, Y | 1 |
Chen, Z | 1 |
Su, W | 1 |
Han, Y | 1 |
Zhao, C | 1 |
Gao, L | 1 |
Ji, X | 1 |
Foltynie, T | 1 |
Pottegård, A | 1 |
Cash, R | 2 |
Ruberg, M | 1 |
Raisman, R | 1 |
Agid, Y | 2 |
Chopde, CT | 1 |
Hote, MS | 1 |
Mandhane, SN | 1 |
Muthal, AV | 1 |
Lasbennes, F | 1 |
Sercombe, R | 1 |
Seylaz, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
a Randomized, Double Blind, Placebo Controlled Clinical Trial Exploring the Target Engagement and Tolerability of Terazosin Hydrochloride in Patients With Dementia With Lewy Bodies[NCT04760860] | Phase 1/Phase 2 | 40 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for prazosin and Parkinson Disease
Article | Year |
---|---|
Glycolysis as a therapeutic target for Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Drug Delivery Systems; Glycolysis; Humans; Parkins | 2019 |
1 trial available for prazosin and Parkinson Disease
Article | Year |
---|---|
A pilot to assess target engagement of terazosin in Parkinson's disease.
Topics: Adenosine Triphosphate; Dizziness; Humans; Parkinson Disease; Pilot Projects; Prazosin | 2022 |
6 other studies available for prazosin and Parkinson Disease
Article | Year |
---|---|
Hytrin loaded polydopamine-serotonin nanohybrid induces IDH2 mediated neuroprotective effect to alleviate Parkinson's disease.
Topics: alpha-Synuclein; Dopamine; Humans; Indoles; Neurodegenerative Diseases; Neuroprotective Agents; Park | 2022 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Animals; Brain; Disease Progression; Dopamine; Dros | 2019 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, | 2021 |
Adrenergic receptors in Parkinson's disease.
Topics: Clonidine; Dihydroalprenolol; Frontal Lobe; Humans; Locus Coeruleus; Neural Pathways; Norepinephrine | 1984 |
Glucocorticoids attenuate haloperidol-induced catalepsy through adrenal catecholamines.
Topics: Adrenalectomy; Animals; Catalepsy; Catecholamines; Glucocorticoids; Haloperidol; Male; Parkinson Dis | 1995 |
Adrenergic receptors on cerebral microvessels in control and parkinsonian subjects.
Topics: Aged; Alprenolol; Capillaries; Cerebrovascular Circulation; Clonidine; Dihydroalprenolol; Humans; Ki | 1985 |